Tuberculosis endemicity and BCG vaccination: Protection against COVID-19 | Zendy

Tarun Krishna Boppana | Zendy; Saurabh Mittal | Zendy; Karan Madan | Zendy; Anant Mohan | Zendy; Vijay Hadda | Zendy; Randeep Guleria | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tuberculosis endemicity and BCG vaccination: Protection against COVID-19

Author(s) -

Tarun Krishna Boppana,

Saurabh Mittal,

Karan Madan,

Anant Mohan,

Vijay Hadda,

Randeep Guleria

Publication year - 2022

Publication title -

monaldi archives for chest disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.196

H-Index - 46

eISSN - 2465-101X

pISSN - 1122-0643

DOI - 10.4081/monaldi.2022.2281

Subject(s) - incidence (geometry) , tuberculosis , medicine , vaccination , case fatality rate , population , bcg vaccine , covid-19 , immunology , disease , environmental health , infectious disease (medical specialty) , pathology , physics , optics

The coronavirus disease 2019 (COVID-19) has affected different countries in a differential manner. The host susceptibility and host factors are important parameters for this variability. This study aimed to assess the effect of tuberculosis (TB) endemicity and Bacille Calmette-Guerin (BCG) coverage on COVID-19. Available data regarding TB incidence, BCG coverage (as per the World Health Organization), and COVID-19 incidence of 168 countries as of 19th September 2021was collected. Countries were divided into four cohorts based upon annual TB incidence and BCG coverage and COVID-19 incidence and case fatality rates were compared using the Kruskal-Wallis test. Countries with low TB incidence and low BCG coverage had the highest COVID-19 incidence per lac population. However, no significant difference was seen in COVID-19 cases fatality rate. Higher TB incidence and BCG coverage were associated with lesser incidence of COVID-19. This result paves the way for research into pathogenesis and host immune response in COVID-19.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research